CliffBio
small molecule

OMEGAVEN

FISH OIL TRIGLYCERIDES

Loss of exclusivityJuly 2026latest FDA-listed patent expiry
CompanyFresenius Kabi →View the full company profile on CliffBio

Drug detail

Brand nameOMEGAVEN
Active ingredientFISH OIL TRIGLYCERIDES
Strength10GM/100ML (0.1GM/ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

Listed patents

PatentExpiresType
9566260July 2026product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OMEGAVEN patent cliff — loss of exclusivity July 2026 | CliffBio